Earliest studies have reported that MVP was overexpressed in various non-Pgp MDR cancers like ovarian carcinoma, AML, oral squamous cell carcinoma, and osteosarcoma; it was correlated with poor prognosis of patients and increased potential for metastasis [72,84,85,86,87,88]. Here, MVP is linked to osteosarcoma.